Neurofibromatosis Type 2
1
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Recursion PharmaceuticalsREC-2282
SandozRAD001, everolimus
Heidelberg PharmaWhole exome sequencing
Clinical Trials (3)
Total enrollment: 99 patients across 3 trials
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas
Start: Jun 2022Est. completion: Aug 202525 patients
Phase 2/3Terminated
Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma
Start: Jul 2015Est. completion: Feb 20244 patients
Phase 2Terminated
WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data
Start: Jul 2017Est. completion: Jul 201870 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.